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Introduction
A number of viral vector systems including those based on modified adenovirus, 1 adeno-associated virus, 2 packaged amplicons 3 and genomic herpes simplex virus, 4 have been demonstrated to be capable of the transfer and constitutive expression of transgenes in the brain in experimental models. However, a limitation of these vectors is the absence of a promoter system that would allow safe and efficient regulation of transgene expression in the nervous system, a property which for certain applications is likely to be important in the use of gene transfer as a therapeutic tool. Promoter systems based on regulatable chimeric transactivators which may be safely used in vivo have recently been developed. In these systems, the transgene to be regulated is placed under transcriptional control of a minimum promoter which in turn is activated by the transactivator. The ability of the transactivator to bind to the promoter and thus activate expression of the transgene may be regulated either by tetracycline 5 or by RU486 (mifepristone). 6, 7 The RU486 responsive system is particularly well suited for central nervous system (CNS) applications because systemically administered RU486 readily crosses the blood-brain barrier, 8 and the drug has been determined to be safe for use in humans. 9 The RU486-inducible transactivator is a tripartite molecule consisting of a mutated RU486-sensitive hormonebinding domain (HBD) from the progesterone receptor, fused to a construct containing the yeast GAL4 DNA binding domain and the acidic activation domain of the HSV VP16 protein. 6 The GAL4:VP16 molecule binds to GAL4-binding sequences in DNA, but fusion of the mutated HBD to the GAL4:VP16 sequences results in a recombinant protein which in its native state is unable to bind to these sequences and therefore unable to mediate transcription. Binding of RU486 to the mutated HBD alters the conformation of the protein, allowing binding to the GAL4 promoter elements and activation of transcription (Figure 1b) . 6 The mutated HBD employed in this system binds the antiprogestin RU486, but is unresponsive to the natural ligand, progesterone. 6 We have previously demonstrated that a constitutive GAL4:VP16 transactivator construct inserted into a replication incompetent herpes simplex virus (HSV) vector functions to drive reporter gene expression from a minimum GAL4 sensitive promoter. 10 In order to allow regulation of gene expression we constructed a recombinant HSV vector with the RU486-inducible promoter system. The double recombinant vector (GVHLZ) contained a lacZ reporter gene under transcriptional control of a GAL4 sensitive promoter and the RU486-inducible transactivator under the transcriptional control of the human cytomegalovirus immediate-early promoter (HCMV IEp). We found that lacZ expression from this vector is strongly induced by treatment with RU486 both in infected cell cultures and in vivo following vector infection of rat hippocampal neurons.
Results

Generation of the drug inducible vector GVHLZ
The vector GVHLZ (Figure 1a) , a double recombinant HSV-vector containing both a lacZ reporter gene and the inducible transactivator, was created in two steps. First the bacterial lacZ gene under control of a GAL4 minimum promoter consisting of five tandem GAL4-binding sites and the TATA box sequences from the adenovirus E1b gene was inserted into the thymidine kinase locus of a replication-deficient HSV vector deleted for the gene coding for ICP4 (d120) 11 to yield the vector G4TATA-lacZ. 10 We have previously demonstrated that this vector produces very low levels of ␤-galactosidase (␤-gal) following infection of Vero cells in culture and no detectable ␤-gal after inoculation into brain, 10 and that when the transactivator GAL4:VP16 is supplied from another virus or from a second location in the same virus the reporter gene is expressed at high levels. 10 The inducible transactivator (VP-GL) was introduced into the glycoprotein C (gC) locus of the G4TATA-lacZ vector by homologous recombination with an expression cassette containing sequences coding for the VP-GL fusion protein under transcriptional control of the strong constitutive human cytomegalovirus immediate-early promoter (HCMV IEp). The HCMV IE promoter has previously been shown to express transgenes efficiently from replication-deficient HSV vectors. 4 Polyadenylation sequences from the gamma 2A immunoglobin gene were added 3′ to the fusion protein sequences in order to ensure efficient transcript termination and polyadenylation. 12 LacZ expression from the vector GVHLZ is induced in response to RU486 in cell culture The ability of the inducible transactivator in GVHLZ to activate the lacZ reporter gene in an RU486-dependent manner was assayed in vitro after infection of Vero cells at a multiplicity of infection (MOI) of 0. Reporter gene expression from the vector GVHLZ is induced in rat hippocampus by systemic treatment with RU486 The ability of RU486 to induce expression of the lacZ transgene from the vector GVHLZ was tested in vivo. Five microliters containing 2 × 10 6 p.f.u. of GVHLZ was injected stereotactically into the hippocampus of 200-250 g Sprague-Dawley rats. At 12 and 36 h after infection the animals were injected either with RU486 (25 mg/kg i.p.) or with saline (control). At 48 h after infection, control and experimental animals were killed and the brains assessed for ␤-gal expression by immunohistochemistry and by soluble assay (Galacto-light Plus assay; Tropix, Bedford, MA, USA). The presence of the vector was demonstrated by immunostaining with a polyclonal antiserum against HSV. HSV-positive neurons were detected in all animals injected with the vector (Figure 5a and b) , but ␤-gal was detected only in animals treated with RU486 (Figure 5c and d) . By morphologic criteria, the vast majority of both HSV and ␤-gal-positive cells were neurons. Quantification of ␤-gal activity by galactolight assay indicated that the amount of ␤-gal activity in control animals was barely detectable above background. Extracts from hippocampus of RU486 treated animals showed approximately 150-fold greater ␤-gal activity than controls (Figure 6 ). Because the assay is capable of detecting as little as 2 fg of ␤-gal, these data suggest a tight on/off switch for gene expression in the context of an HSV gene transfer vector.
Discussion
Transgene expression in brain has been previously demonstrated with a variety of different viral vectors in which transgene expression from the vector is driven by constitutive promoters. However, for clinical applications it may be desirable or necessary to regulate transgene expression from the vector genome with a drug which can be safely administered systemically. Several promoter systems are available which are capable of regulating gene expression in eukaryotic cells. These include promoters whose activity is altered in response to heavy metal ions, 13, 14 hormones, [15] [16] [17] [18] isopropyl-␤-d-thiogalactoside, 19 tetracycline 5 or to RU486. 6 The metallothionein promoter, the tetracycline (tet) inducible system and a tripartite system based on ecdysone have been tested in transgenic animals 14, 18, [20] [21] [22] [23] [24] and the tet system has been used in a HSV amplicon vector to regulate reporter gene expression in brain. 25 Based on these reported results, we believe that the RU486 system utilized in our vector compares favorably with these other inducible systems for regulation of transgene expression in brain.
The metallothionein promoter has been used exten-
Figure 3 Dose-response relationship in vitro. Activation of the lacZ reporter gene in GVHLZ was monitored by ONPG after infection of Vero cells at MOI of 1 in the presence of different concentrations of RU486. Cultures were harvested at 48 h after infection.
Figure 4 Time course of reporter gene activation in vitro. Vero cells were infected with GVHLZ (MOI 1) and 28 h after infection RU486 was added to all cultures (10 −7 m final concentration). Cultures were harvested at indicated time points and assayed for ␤-gal activity by ONPG assay.
sively to overexpress transgenes in transgenic mice, with expression induced following treatment with heavy metals. However, in brain there appears to be significant expression in the uninduced state, and the levels of induction achieved with treatment ranges from 1.4-to 15-fold. 14, [20] [21] [22] Because of the known toxicity of systemically administered heavy metals this system will have severe limitations as a therapeutic tool in humans. 26 A recently described inducible system based on the ecdysone receptor has been found to be capable of regulating transgene expression in vivo. 18 This steroidresponsive system is superior to inducible systems based on responsiveness to human steroids [15] [16] [17] as the insect hormone ecdysone does not affect endogenous gene expression due to a lack of functional ecdysone receptors a b c d
Figure 5 The vector GVHLZ expresses lacZ in an RU486-dependent manner in rat brain. Sections of hippocampus injected with the vector GVHLZ from either drug or mock-treated animals were tested for the presence of HSV and ␤-galactosidase antigens by immunohistochemistry as described in Materials and methods. Both mock-and drug-treated animals demonstrated large numbers of HSV antigen-positive cells (a and b) demonstrating the presence of vector in the tissue. HSV-positive cells from animals not treated with drug showed no reactivity with the ␤-galactosidase antibody (c). In contrast vector-containing cells from the animals treated with 25 mg/kg RU486 also reacted strongly with the ␤-galactosidase antibody indicating strong expression of the lacZ transgene (d).
Figure 6
The level of transgene activation was quantified by measuring the ␤-galactosidase present in brains from untreated and RU486-treated animals using a soluble assay. ␤-Galactosidase activity was increased 150-fold in animals treated with RU486.
on mammalian cells. Therefore only cells which have been transduced with both a transgene under control of an ecdysone responsive promoter and the bipartite ecdysone receptor will be capable of responding to ecdysone treatment. In vivo analysis of this system in transgenic mice indicates that the system can regulate gene expression in a highly specific manner in thymus. 18 However, no quantification of induction has been reported and the ability of the system to activate gene expression in the brain has not been addressed. 18 Transgenic mice experiments with the tetracyclineregulated transactivation system indicated that a sevento 100-fold derepression of transgene expression could be obtained in brain following removal of tetracycline 23, 24, 27 suggesting the feasibility of using this system in the context of a gene therapy vector. Recently the efficacy of the system when incorporated into a HSV amplicon vector was examined in rat hippocampus. 25 Quantitative analysis of luciferase expression from this vector determined that an approximately 10-fold increase in reporter gene activity could be detected 5 days following derepression by removal of tetracycline. However, derepression was much less robust at earlier time points and significant expression of the reporter gene was detected in the presence of tetracycline. 25 The RU486-inducible system has several aspects which make it attractive for use in regulating transgene expression in brain. First, transgene expression was highly specific with expression in the uninduced state barely above background. Second, a high level of induction was observed following treatment with drug (150-fold). Third, the dose of drug necessary to produce detectable protein product is within the range acceptable for clinical use. 9 Also, the system could be employed in other viral vectors because of the small size of the transactivator expression cassette (Ͻ2.0 kb). Theoretically, the RU486 system can be used in combination with the tetracycline system to generate vectors in which the expression of two transgenes are differentially modulated. The data presented demonstrate a 'proof-of-principle' that the RU486 system may be used to induce HSV transduced transgene expression in brain.
Materials and methods
Cell culture and virus stock production Vero, African green monkey kidney, cells (ATCC, Rockville, MD, USA; CCL81), and E5 cells 11 were maintained in minimal essential medium supplemented with glutamine, antibiotics (PSN) and 10% fetal calf serum (LTI, Gaithersburg, MD, USA). Virus stocks were prepared as previously described. 28 
Plasmid and vector construction
Plasmid pgC/HCMV-(VP-GL): The sequences for the chimeric transactivator VP-GL 6 were placed downstream of the HCMV promoter and 5′ to the polyadenylation sequences from the mouse gamma 2A immunoglobin gene. 12 This expression cassette was cloned into a plasmid containing the sequences from the gC locus as a HindIII-PacI fragment. This subclone results in a recombination plasmid deleted for the HSV sequences 96311-96751. The flanking HSV sequences are as follows 5′ 94853-96311; 3′ 96751-98422. HSV genome sequences refer to strain 17 sequence.
The vector G4TATA-lacZ: Vector G4TATA-lacZ was created by inserting a lacZ gene under control of a minimum GAL4 promoter in the tk locus of the ICP4 − virus d120 as previously described. 10 Briefly, the expression cassette was introduced into the genome of the ICP4 − virus d120
11 by homologous recombination. Recombinants were identified by selection with gancyclovir at a concentration of 5 g/ml. Gancyclovir-resistant plaques were isolated and tested for the presence of the lacZ by Southern analysis. Isolates which contained the lacZ cassette were purified by three rounds of limiting dilution. ␤-Galactosidase assays: ␤-galactosidase (␤-gal) expression from recombinant viruses was monitored by X-gal staining of plaques and cell monolayers. Cells were stained by fixing in 4% paraformaldyhyde (Sigma, St Louis, MO, USA) for 2 min followed by three washes in PBS pH 7.5. Fixed plaques were stained by incubation in X-gal staining solution (1 mg/ml X-gal; Boehringer Mannheim, Indianapolis, IN, USA) in TBS pH 8.0 + (5 mm K 4 Fe(CN) 6 , 5 mm K 3 Fe(CN) 6 until blue color was observed.
␤-Gal activity in infected cell cultures was quantified by ONPG assay. Infected cell monolayers were harvested 24 h after infection and lysed by three rounds of freezethawing before use. ONPG assays were performed as described in the laboratory manual Molecular Cloning. 29 ␤-Gal activity in brain homogenates was quantified using the Galacto-light Plus assay. This assay uses the chemiluminescent substrate AMPGD (3-(4-methoxyaprio [1,2-dioxethane-3.2′-tricyclo[3.3.1.1 3, 7 ] decan-4-yl) phenyl-␤-dgalactopyranonside), which allows for the detection of as little as 2 fg (0.015 amol) of ␤-gal. 30, 31 Injected hippocampus was isolated from animals 48 h after infection and homogenized in lysis solution (100 mm potassium phosphate pH 7.8, 0.2% Triton X-100, 1 mm DTT, 0.2 mm phenylmethylsulfonyl fluoride (Sigma) and 5 mg/ml leupeptin (Sigma)). The samples were then centrifuged at 12 500 g for 10 min at 4°C and the supernatant was removed and heated at 48°C for 60 min. After recentrifugation for 5 min, 20 l of the extract was placed with 80 l of Galacto-Light reaction buffer and incubated for 20 min at room temperature. Subsequently 100 l of accelerator buffer was added and emission detected for 5 s with a luminometer. Protein concentration was determined by a standard Bio-Rad assay (Bio-Rad, Richmond, CA, USA), and the ␤-gal activity expressed as relative light units (RLU) per min per milligram of protein. Four animals were tested in both the experimental (RU486-treated) and control (untreated) groups.
Stereotactic injection into rat brain and drug treatment:
Male Sprague-Dawley rats weighing 250-300 g were stereotactically injected with 5 l of the GVHLZ vector containing 2 × 10 6 p.f.u. into the rat hippocampus according to the coordinates of Paxinos and Watson.
32 RU486 (25 mg/kg) was administered to animals by i.p. injection 12 h after vector delivery and again 24 h later. RU486 for injection was dissolved in 70% ethanol.
Immunocytochemistry: Forty-eight hours after inoculation, animals were perfused with 4% paraformaldehyde, the brains harvested and cryoprotected in 30% sucrose in PBS. Floating sections 40 m in size, were stained simultaneously with a mouse monoclonal anti-␤-gal antibody (Sigma; 1:1000) and a rabbit polyclonal anti-HSV antibody (Accell, Westbury, NY, USA; 1:2000). A biotinylated sheep anti-mouse secondary antibody (Amersham, Arlington Heights, IL, USA; 1:250) and Streptavidin Texas Red (GIBCO-BRL, Grand Island, NY, USA; 1:250) were used to detect the ␤-gal antibody, and the anti-HSV antibody detected with a donkey anti-rabbit FITC-conjugated antibody (Chemicon, Temecula, CA, USA; 1:250). Slides were mounted in Fluoromount (Gurr, BDH, Poole, UK) and viewed with filters to detect Texas Red and FITC fluorescence. Four animals treated with RU486 and four control animals were killed for immunocytochemistry.
